is part of the Informa Markets Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Cellspect’s innovative Point-of-Care Testing (POCT) solutions are ushering you to a new era of simple, fast, and accurate blood testing which can be easily done by yourself at home, work, or anywhere else. Cellspect has also improved conventional POCT into smart device-driven POCT that enables detection by using mobile Apps, bringing true self-testing to a new digital age.
Abdul Latif Jameel General Trading based in Tokyo, Japan, part of the diversified family business Abdul Latif Jameel, announced a new collaboration with Cellspect for the distribution of the Cellspect blood testing in the Middle East, Africa, Southeast Asia, and India.
Cellspect, based in Japan, develops and produces next-generation POCT (Point of Care Testing) devices that detects multiple parameters simultaneously from limited samples, such as fingertip blood. Moreover, in the view of the rapidly changing digital transformation, Cellspect has improved POCT into smart device-driven POCT which enables detection by using mobile Apps. Currently, biochemical tests such as ‘sugar metabolism’, ‘lipid’ and COVID-19 antigen/antibody are available and more tests on cardiovascular diseases, infectious diseases, and even customized tests will be released in the future. By providing items and tools that allow people to easily know their health, Cellspect would like to take on the challenge of realizing “Barrier-Free Health” that allows anyone to access healthcare freely.